What is invasive meningococcal disease?

Invasive meningococcal disease (IMD) is caused by Neisseria meningitidis entering the bloodstream from the nasopharynx (where it is normally carried harmlessly). It manifests as: meningococcal meningitis (inflammation of brain/spinal cord lining — neck stiffness, headache, photophobia, fever); meningococcal septicaemia/bacteraemia (bloodstream infection — fever, petechial/purpuric non-blanching rash — the most dangerous form); or both simultaneously. Despite antibiotics, approximately 10-14% of patients die, and 10-20% of survivors have permanent disabilities — deafness, limb amputation (from ischaemic necrosis), brain damage.

What is the classic clinical presentation?

IMD progresses rapidly — from feeling unwell to death in as little as 24 hours. Early: flu-like illness (fever, headache, myalgia, malaise) — easily mistaken for influenza. Red flag signs: non-blanching petechial or purpuric rash (approximately 85% of septicaemia cases); photophobia (intolerance of light); neck stiffness (meningism — most specific); severe persistent headache; altered consciousness; cold hands/feet with mottled skin; unusual colour to skin. The classic triad (neck stiffness, fever, altered consciousness) is present in only approximately 50% of meningococcal meningitis cases — do not wait for all three before acting.

When should antibiotics be given?

IMMEDIATELY when meningococcal disease is suspected — in the community, by the GP or emergency services, before hospital transfer, and certainly before lumbar puncture. Benzylpenicillin (penicillin G): 1.2g IV or IM (adults) — or if not available, oral amoxicillin 3g; reduces mortality even when given pre-hospital. Ceftriaxone 2g IV (alternative if penicillin allergy). Hospital: ceftriaxone 2g IV 12-hourly; add dexamethasone 0.15mg/kg 6-hourly × 4 days (to reduce meningitis inflammation and hearing loss risk). NEVER delay antibiotics for LP — give antibiotics, then LP if safe.

Which meningococcal vaccines are available?

Two separate vaccine types are needed for complete protection: MenACWY (against serogroups A, C, W, Y): Nimenrix or Menveo conjugate vaccines; recommended for adolescents 11-18 years; required for Hajj pilgrims; for close contacts of confirmed IMD. MenB (against serogroup B — the most common in Europe): Bexsero (4CMenB) or Trumenba; 2-dose schedule for adolescents; infant schedule for highest risk. No single vaccine covers all five pathogenic serogroups. PentaBio (Pfizer 2024): a combined MenABCWY vaccine in clinical trials — could simplify vaccination.

What are close contacts and what prophylaxis do they need?

Close contacts who must receive chemoprophylaxis within 24 hours: people who have slept in the same household as the case in the preceding 7 days; people who have had direct oral contact (kissing) with the case; healthcare workers with unprotected exposure to respiratory secretions (without a mask). Ciprofloxacin 500mg single oral dose (adults) — the preferred regimen: eliminates nasopharyngeal carriage. Rifampicin 600mg twice daily × 2 days (alternative). Ceftriaxone 250mg IM single dose (in pregnancy). Public health authorities must be notified immediately of any IMD case to coordinate contact tracing.

How does GMJ News cover invasive meningococcal disease?

GMJ News covers WHO IMD data, ECDC CC11 serogroup W emergence, the non-blanching rash emergency sign, immediate pre-hospital antibiotics, MenACWY and MenB vaccination, ciprofloxacin contact prophylaxis, and Waterhouse-Friderichsen syndrome. IMD — with its rapid, devastating progression — is one of the most important paediatric and adolescent infectious emergencies and directly relevant to PHIG's immunisation programme and Georgia's meningococcal vaccination policy.

Home › Topics › Invasive Meningococcal Disease

Invasive Meningococcal Disease

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Invasive meningococcal disease (IMD) — caused by Neisseria meningitidis serogroups A, B, C, W and Y — kills approximately 135,000 people per year globally with a case fatality rate of 10-14% despite optimal treatment, and leaves permanent disability (deafness, limb amputation, brain damage) in 10-20% of survivors; the defining clinical emergency is the non-blanching petechial or purpuric rash of meningococcal septicaemia, which demands immediate IV benzylpenicillin or ceftriaxone — before hospital transfer, before lumbar puncture (WHO). Major recent concern: the hypervirulent clonal complex CC11 driving a resurgence of serogroup W meningococcal disease across Europe and the Americas since 2013, with an “atypical” presentation (GI symptoms, confusion) that delays diagnosis. Effective MenACWY and MenB vaccines can prevent the disease.

Key messages

135K deaths/year — 10-14% CFR despite treatment

Invasive meningococcal disease causes approximately 1.2 million cases and 135,000 deaths per year globally. Despite optimal treatment, 10-14% of patients die — and 10-20% of survivors have permanent disability: deafness, limb amputation, brain damage (WHO).

Non-blanching rash — the emergency sign

A non-blanching (petechial or purpuric) rash that does not fade when pressed with a glass tumbler is the pathognomonic sign of meningococcal septicaemia. It indicates embolic spread of bacteria from septicaemia. This is a medical emergency.

Antibiotics BEFORE hospital — before lumbar puncture

If meningococcal disease is suspected: give IM or IV benzylpenicillin (or ceftriaxone) IMMEDIATELY — in the community if possible, before transfer to hospital, and certainly before performing a lumbar puncture. The 30-60 minute delay for lumbar puncture is too costly; LP can be done in hospital after antibiotics.

Serogroup W — hypervirulent clonal complex CC11

Since 2013, hypervirulent meningococcal serogroup W (MenW CC11) has been spreading across Europe and the Americas, causing severe invasive disease with atypical presentations (GI symptoms, septic arthritis, pneumonia — mimicking other diagnoses) that delay recognition. This strain has a CFR >20%.

MenACWY + MenB — two separate vaccine targets

Complete meningococcal vaccination requires two different vaccines: MenACWY (Nimenrix, Menveo — conjugate vaccine protecting against serogroups A, C, W, Y); MenB (Bexsero 4CMenB, or Trumenba — recombinant protein vaccines against serogroup B, the most common serogroup in Europe).

Chemoprophylaxis for close contacts

All close contacts of a confirmed IMD case must receive chemoprophylaxis: ciprofloxacin 500mg single oral dose (adults) — the most effective and convenient regimen; rifampicin 600mg BD × 2 days (alternative); ceftriaxone 250mg IM (in pregnancy). Close contact = household contact, sleeping in same room, direct contact with oral secretions.

Key statistics

~1.2M

invasive meningococcal disease cases/year globally

WHO

135K

meningococcal deaths/year globally

WHO

10-14%

case fatality rate despite optimal antibiotic treatment

WHO/ECDC

10-20%

of survivors have permanent disability

WHO/ECDC

CC11

hypervirulent clonal complex W spreading in Europe/Americas since 2013

ECDC 2024

Ciprofloxacin

single-dose oral chemoprophylaxis of choice for close contacts

WHO/PHE

Meningococcal serogroup distribution in Europe — ECDC annual data

Source: ECDC. Serogroup B remains dominant in Europe; serogroup W CC11 rising since 2013.

Glossary of key terms

Neisseria meningitidis
WHOA Gram-negative diplococcus — an obligate human pathogen; colonises the nasopharynx asymptomatically in approximately 10-35% of healthy adults (carriage). Five pathogenic serogroups (A, B, C, W, Y) defined by polysaccharide capsule structure. Invasion from the nasopharynx to bloodstream triggers explosive septicaemia and/or meningitis.

Petechial/purpuric non-blanching rash
WHO/ClinicalPetechiae: pinpoint (<2mm) red/purple spots — from microhaemorrhages; purpura: larger (>2mm) purple lesions. NON-BLANCHING: when a glass tumbler is pressed firmly on the rash, it does NOT turn white (unlike a reactive hyperaemia rash) — because the extravasated red cells cannot be compressed back into vessels. Initially may appear on trunk, then rapidly spreads. In fulminant septicaemia, lesions coalesce into large purpuric patches — skin infarction (the most dire prognostic sign).

Waterhouse-Friderichsen syndrome
WHO/ClinicalBilateral adrenal haemorrhage and adrenal insufficiency in the context of overwhelming meningococcal septicaemia. Causes refractory septic shock and circulatory collapse. Characterised by: massive purpuric skin lesions; rapid cardiovascular collapse; adrenal insufficiency requiring IV hydrocortisone. Associated with DIC (disseminated intravascular coagulation).

MenB vaccines
EMA/FDA4CMenB (Bexsero, GSK): contains four meningococcal B outer membrane protein antigens (fHbp, NadA, NHBA, outer membrane vesicles); 2-dose schedule for adolescents or infants (0,2,4 months + booster at 12 months). Trumenba (Pfizer): bivalent rLP2086 fHbp vaccine; 2 or 3-dose schedule. Coverage against MenB strains is partial (approximately 66-88% of strains covered) due to antigenic variability. Bexsero also provides approximately 40% protection against gonorrhoea (cross-reactivity).

MenACWY vaccine
WHO/EMAQuadrivalent conjugate vaccines (Nimenrix, GSK; Menveo, GSK) — polysaccharide antigens for serogroups A, C, W, Y conjugated to protein carrier (tetanus toxoid or CRM197). Single dose for adolescents ≥12 months; boosters every 5 years in high-risk groups. The “meningitis belt” (Sub-Saharan Africa) uses MenA conjugate vaccine (MenAfriVac) specifically for serogroup A — responsible for massive meningococcal epidemics in the region.

CC11 (Clonal Complex 11) serogroup W
ECDCA hypervirulent meningococcal lineage — emerged in the Hajj pilgrimage in 2000, then re-emerged as a divergent variant causing epidemic disease in South America and Europe from approximately 2013. CC11 W causes: higher case fatality (approximately 20-25%); older age groups (less typical adolescent peak); atypical presentations — GI symptoms (nausea, vomiting, diarrhoea), septic arthritis, pneumonia — that delay diagnosis; rapid progression to septicaemia. ECDC identified CC11 W as the major IMD threat in Europe 2020-2025.